Today’s innovative acne treatments include blue light therapy and Isolaz laser acne treatments, but these aggressive treatments may not be necessary if a new topical product makes its way into the consumer market.
NanoBio Corporation, a privately held biopharmaceutical company based in Ann Arbor, Michigan, revealed new data about its innovative nanoemulsion-based product for the treatment of acne at the Academy of Dermatology Summer Meeting in Boston the week of July 29. The NB-003 product works by targeting the oil-producing glands connected to the hair follicle, and treating the infection site by killing the microbes on contact. It is the first of its kind to reach deep within into the skin tissues and kill bacteria within seconds, and will be undergoing ongoing review by clinical researchers.
Acne can be triggered by a number of factors including stress, poor skin health, an unbalanced diet, or be the result of hormonal imbalances. In some cases, addressing the root cause of the problem can help. However, many people are not able to trace the cause of the problem and must pursue an ‘outside in’ approach to achieve healthier skin. This may include the application of topical retinoids, taking oral contraceptives, or undergoing a series of laser or light treatments.
If this topical acne treatment is successful, many patients will no longer need to take birth control pills to manage their acne symptoms, or undergo expensive laser or blue light therapy acne treatments to keep breakouts under control.
NanoBio Corp. has been developing other types of anti-infective products to treat cold sores, tinea capitis, cystic fibrosis and nail fungus. If the acne treatment becomes available in the United States, it may be an attractive alternative for many acne sufferers who have not been able to achieve results with conventional acne treatments such as topical retinoids, blue light therapy or Isolaz laser acne treatments.